Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138,481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.
Yang G, Su X, Huang Y, Luo G, Wang Z, Cai P, Zheng Y, Bei T, Huang M, Bai Y, He H, Xiang J, Cai M, Zhong J, Guo Q, Zhang X. Yang G, et al. Among authors: wang z. J Transl Med. 2023 Jun 24;21(1):411. doi: 10.1186/s12967-023-04273-6. J Transl Med. 2023. PMID: 37355621 Free PMC article. Clinical Trial.
A 3-Year Survival Update from a Phase 2 Study of Paclitaxel Plus Cisplatin and 5-Fuorouracil Induction Chemotherapy for Locally Advanced Borderline-Resectable Esophageal Squamous Cell Carcinoma: The NEOCRTEC-1601 Clinical Trial.
Wu JD, Wang ZQ, Li QQ, Li ZC, Ren C, Wang DS, Chen JY, Tan Q, Li YH, Yang H. Wu JD, et al. Ann Surg Oncol. 2024 Feb;31(2):838-846. doi: 10.1245/s10434-023-14513-0. Epub 2023 Nov 2. Ann Surg Oncol. 2024. PMID: 37919448 Free PMC article. Clinical Trial.
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS, Ren C, Li SS, Fong WP, Wu XJ, Xiao J, Li BK, Zheng Y, Ding PR, Chen G, Qiu MZ, Wang ZQ, Wang FH, Luo HY, Wang F, Wang XZ, Wang LY, Xie DJ, Chen T, Li LR, Lu ZH, Zhai XH, Liu TS, Yuan Y, Chen JQ, Tan Q, Pan ZZ, Wan DS, Zhang R, Yuan YF, Xu RH, Li YH. Wang DS, et al. PLoS Med. 2024 May 10;21(5):e1004389. doi: 10.1371/journal.pmed.1004389. eCollection 2024 May. PLoS Med. 2024. PMID: 38728364 Free PMC article. Clinical Trial.
Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration.
Lu Y, Jin Y, Liu F, Wang Z, Zhou W, Zhang Y, Bai B, Wang Y, Wang Z, Nie M, Luo H, Wei X, Liang C, Guo G, Qiu M, Chen J, Liu Y, Li S, Li Y, Wang F, Wang F, Chi P, Zhang D. Lu Y, et al. Among authors: wang f, wang z, wang y. Cancer Immunol Immunother. 2024 Sep 5;73(11):220. doi: 10.1007/s00262-024-03796-1. Cancer Immunol Immunother. 2024. PMID: 39235609 Free PMC article.
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.
Zou X, Ding X, Feng ZK, Ouyang YF, Li HF, Wen K, Wang ZQ, Liu YP, Liu YL, Zhang WJ, Yang Q, Chen SY, Xie YL, Xie RQ, Lin C, Gu CM, Huang PY, Sun R, Hua YJ, You R, Chen MY. Zou X, et al. Cell Rep Med. 2024 Oct 15;5(10):101779. doi: 10.1016/j.xcrm.2024.101779. Cell Rep Med. 2024. PMID: 39413735 Free PMC article. Clinical Trial.
138,481 results
You have reached the last available page of results. Please see the User Guide for more information.